2006
Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
O’Connor K, Roy SM, Becker CH, Hafler DA, Kantor AB. Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers. Disease Markers 2006, 22: 213-225. PMID: 17124343, PMCID: PMC3851054, DOI: 10.1155/2006/670439.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMultiple sclerosisMagnetic resonance imagingPutative biomarkersComprehensive phenotypingMonitoring of progressionComponent expression levelsClinical evaluationCSF proteinAccurate biomarkersCerebrospinal fluid chemistryControl groupTherapeutic interventionsPatient careAccurate diagnosisResonance imagingDisease pathologyFurther evaluationBiomarkersPreliminary dataExpression levelsSclerosisDiagnosisCSFSingle testNovel assessment
1993
Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis
Weiner H, Mackin G, Matsui M, Orav E, Khoury S, Dawson D, Hafler D. Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis. Science 1993, 259: 1321-1324. PMID: 7680493, DOI: 10.1126/science.7680493.Peer-Reviewed Original ResearchConceptsMultiple sclerosisOral tolerizationMyelin antigensAutoimmune diseasesDouble-blind pilot trialRelapsing-remitting multiple sclerosisDouble-blind studyCentral nervous systemMyelin basic proteinMajor exacerbationsDaily capsuleT cellsT lymphocytesPilot trialSide effectsNervous systemControl groupMyelin componentsBovine myelinDiseaseMyelinTolerizationSclerosisAntigenBasic protein